|
| |
Vanda PharmaceuticalsVanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients.
Our CEO, Mihael Polymeropoulos, MD, founded Vanda in 2003. Previously, he founded and ran the Novartis global Pharmacogenetics department, one of the industry leaders. Prior to that he worked for many years at the National Institute of Mental Health and the National Human Genome Research Institute, where he did pioneering work in gene mapping. He founded Vanda in partnership with Care Capital LLC, the prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises.
Vanda has assembled an experienced team and a stable of clinical stage compounds to deliver on its vision.
| Contact Details: |
| 9605 Medical Center Drive, Suite 300 |
| Rockville |
| Maryland |
| 20850 |
| United States of America |
| Tel: | 240.599.4500 |
| Fax: | 301.294.1900 |
| Email: | |
| WWW: | www.vandapharma.com/
|
|
Loading...
|
Recent Publications by Vanda Pharmaceuticals: |  |
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
OBJECTIVE: To demonstrate how several polymorphisms previously associated... | 21st July, 2009
| Vanda Pharmaceuticals Inc, Rockville, MD 20850, USA.
| J Clin Psychiatry. 2009 Jun;70(6):801-9.
|
Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia.
For decades, the dopamine hypothesis has gained the most attention in an... | 17th June, 2009
| Vanda Pharmaceuticals Inc., 9605 Medical Center Drive, Rockville, Maryland
| Schizophr Res. 2009 Mar;108(1-3):134-42. Epub 2009 Jan 15.
DOI Direct Link |
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Administration of certain drugs (for example, antiarrhythmics,... | 4th June, 2008
| Vanda Pharmaceuticals Inc., Rockville, MD 20850, USA.
| Mol Psychiatry. 2009 Nov;14(11):1024-31. Epub 2008 Jun 3.
DOI Direct Link |
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
A whole genome association study was performed in a phase 3 clinical trial... | 4th June, 2008
| Vanda Pharmaceuticals Inc., Rockville, MD 20850, USA.
| Mol Psychiatry. 2009 Aug;14(8):804-19. Epub 2008 Jun 3.
DOI Direct Link |
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
AIMS: Presence of the null FS63TER allele of the rs1800169 polymorphism in... | 26th April, 2008
| Vanda Pharmaceuticals Inc, 9605 Medical Center Drive, Suite 300,
| Pharmacogenomics. 2008 Mar;9(3):289-301.
DOI Direct Link |
→View more Vanda Pharmaceuticals research publications. |
Press Releases on Vanda Pharmaceuticals:
|
 |
| Vanda Pharmaceuticals Reports Third Quarter 2009 Results |
2nd November, 2009 |
Vanda Pharmaceuticals Inc. |
-- Operating Expenses. Third quarter 2009 R&D expenses of $2.1 million
consisted primarily of $0.5 million of salaries and benefits, $0.7
million of non-cash stock based
|
| Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 |
6th August, 2009 |
Vanda Pharmaceuticals Inc. |
ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage
|
| Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders |
29th May, 2009 |
Vanda Pharmaceuticals Inc. |
ROCKVILLE, Md., May 29 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2009 Annual Meeting of Stockholders on Thursday, August 27, 2009, in
|
| Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting |
14th May, 2009 |
Vanda Pharmaceuticals Inc. |
ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt(TM)
|
| Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital |
7th May, 2009 |
Vanda Pharmaceuticals Inc. |
ROCKVILLE, Md., May 7 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) ("Vanda" or the "Company") announced today that Tang Capital Partners, LP ("TCP"
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 597 times since April 2007, the link to the organisation's website has been followed 89 times Recent Search Terms used to find this page: vanda pharmaceuticals email list | 9605 Medical Center Drive suite 300 Rockville MD 20850 | vanda bio*one | vanda pharmaceuticals Founded in 2003 in partnership with Care Capital LLC and Bio*One Capital | jULY 2009 PSYCHIATRY pharmaceuticals | vanda medical benefits | logo vanda institute | vanda Pharma email contact | Vanda Pharmaceuticals news july 2009 | vanda pharm | . Search for more companies in Rockville Search for more companies in Maryland This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Vanda Pharmaceuticals |
